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Vitamin D metabolism in nephrotic rats. Vitamin D metabolites were
measured in sera of normal, vitamin D deficient and nonazotemic
nephrotic rats. The concentrations of all metabolites were reduced in
nephrotic and vitamin D deficient animals although I ,25-dihydroxyvita-
mm D values remained relatively normal in the nephrotic group.
Twenty-four hours after the intravenous injection of tritiated 25-
hydroxycholecalciferol, approximately 34% of the injected radioactiv-
ity appeared in the urine of the nephrotic animals compared with 0.4%
in the controls. In extracts from nephrotic sera subjected to high
performance liquid chromatography, the percentage of radioactive
counts comigrating with I ,25-dihydroxycholecalciferol and 24,25-dihy-
droxycholecalciferol was significantly increased. The various metabo-
lites were present in urine in approximately the same ratios as in serum.
Dynamic histomorphometry of tibial metaphyses showed no abnormali-
ty. Urinary losses of vitamin D metabolites constitute the major cause
for low serum values in nephrotic rats. The apparent synthetic rates are
not impaired.
Métabolisme de Ia vitamine D chez des rats néphrotiques. Les metabo-
lites de Ia vitamine D ont été mesurés dans le serum de rats normaux,
carencés en vitamine D, et nephrotiques non urémiques. Les concentra-
tions de tous les métabolites étaient diminuées chez les animaux
nCphrotiques et carencés en vitamine D, bien que les valeurs de 1,25-
dihydroxyvitamine D soient restées relativement normales dans le
groupe nephrotique. Vingt-quatre heures aprés l'injection intraveineuse
de 25-hydroxycholécalciferol tritié, approximativement 34% de Ia ra-
dioactivité injectée apparalsait dans l'urine des animaux nephrotiques
par rapport a 0.4% chez les contrôles. Dans les extraits de serums
nephrotiques soumis a une chromatographie liquide a haute pression, le
pourcentage de radioactivité co-migrant avec le I ,25-dihydroxychole-
calciférol et le 24,25-dihydroxycholécalciférol était significativement
augmente. Les différents mCtabolites Ctaient presents dans l'urine avec
approximativement les mCmes rapports que dans le serum. L'histomor-
phometrie dynamique des metaphyses tibiales n'a pas montré d'anoma-
lie. Les fuites urinaires de mCtabolites de Ia vitamine D constituent Ia
cause majeure de valeurs plasmatiques basses chez les rats néphroti-
ques. Les taux de synthese apparents ne sont pas altérés.
Nephrotic patients with normal creatinine clearance rates
have low serum concentrations of 25-hydroxyvitamin D
(250HD) [1—3], 1,25-dihydroxyvitamin D [l,25(OH),D] [4, 5]
and 24,25-dihydroxyvitamin D [24,25(OH)2D] [4, 5]. Barragry
et al [3] who administered 3H-labeled cholecalciferol to three
nephrotic subjects, observed the appearance of labeled 250HD
in the urine within 24 hr and suggested that the low serum
concentrations of this metabolite were due to urinary losses.
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Lambert et a! [5] described increased urinary losses of
dihydroxylated vitamin D metabolites in nephrotic patients. In
this study we measured the concentrations of 250HD,
1,25(OH)2D, and 24,25(OH)2D in sera of nephrotic rats to
determine whether or not the values were abnormally low in
this animal model, We also measured tritiated 250HD3,
24,25(OH)2D3, and I ,25(OH)2D3 after an intravenous injection
of [3H1250HD3 in an attempt to determine whether or not low
blood concentrations were due solely to urinary losses.
Experimental protocol. Twenty-two male hooded Wistar rats
weighing between 250 to 400 g (mean = 318 32 g) underwent
left nephrectomy. Ten animals were used as controls, five
animals were given a vitamin D-deficient diet, while seven
animals were rendered nephrotic by a modification of the
method of Karlinsky et al [6].
Nephrotoxic serum (NTS) was raised in rabbits given sutcu-
taneous injections of 10 to 12 mg purified rat glomerular
basement membrane [7] in complete Freunds adjuvant every 3
weeks for 14 months. The rabbit sera used in this experiment
were harvested II and 14 months after the first injection and
stored at —20°C until required. They were heated at 56°C for 30
mm and adsorbed with normal rat erythrocytes for 60 mm just
before use.
Seven days after unilateral nephrectomy, each rat to be
rendered nephrotic was given 10 to 12 mg ammonium sulfate-
fractionated gamma globulin from normal rabbits in incomplete
Freunds adjuvant. Half of this material was injected intramus-
cularly and half subcutaneously. Four days and 42 days later
(days 11 and 49, respectively), these animals received I ml NTS
intravenously. The nephrotic syndrome was usually well-estab-
lished by day 70 (Table I) which was 3 weeks after the second
injection of NTS. The other two groups of animals did not
receive injections.
Nephrotic and control animals were fed standard rat chow
(Allied Feeds, Sydney, Australia) containing 1.3% calcium,
0,72% phosphorus, and 2,200 U vitamin D3 per kg. The D-
deficient group was fed a vitamin D-deficient diet containing
similar concentrations of calcium and phosphorus. Their cages
were placed in a dark room.
Urinary protein measurements were made on 24-hr samples
obtained from nephrotic and control animals placed in individ-
ual metabolic cages (Ehret, MUnchen, West Germany) between
days 56 and 59 (14 and 17 days after the second injection of
NTS). On day 67, after an overnight fast, blood was drawn from
the tail artery of these animals for the measurement of serum
creatinine, albumin, and 250HD.
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Table 1. Body weights and biochemical data of sera from normal, nephrotic, and D-deficient rats, 3 and 8 weeks after the second injection of
NTS
Controls
(N = 10)
Nephrotic(N = 7)
D-deficient
(N = 5)
Body weights, g (1)
(2)
324 31
340 36
308 29
336 28
292 6
335 23
Creatinine, mmoleslliter (1)
(2)
0.07 0.0!
0.07 0.01
0.08 0.02
0.07 0.01
NM
0.08 0.01
Albumin, giliter (I)
(2)
33.9 1.7
32.4 1.4
21.1 2.3b
23.6 2.2"
NM
32.0 3.5
Calcium, mmoles/liter" (2) 2.45 0.14 2.58 0.18 2.50 0.17
Inorganic phosphate, mmoles/liter (2) 1.96 0.34(N=8)
2.30 0.54
(N=6)
2.50 0.49
Cholesterol, mmoles/liter (2) 1.49 0.17(N=9)
5.70 1.65"(N=5)
NM
Triglyceride, mmoleslliter (2) 1.54 0.38(N=9)
6.13 2.56'
(N=5)
NM
250HD, mmoleslliter (I)
(2)
73 17
63
13 9"
9 2b
NM
<8
Urine protein, mg124 hr (1) 3 2 229 54" NM
Abbreviations: (1), day 70 (3 weeks after the second injection of NTS); (2), day 105 (8 weeks after the second injection of NTS); NM, Not
measured.
Serum calcium was corrected to a serum albumin concentration of 32 glliter.
b The value is significantly different from control (P < 0.001).
The value is significantly different from control (P < 0.01).
Between days 70 and 74, each animal in the nephrotic and
control groups was given a single intravenous injection of 0.5
Ci 25-hydroxy-[26,27-methyl-3H] cholecalciferol, specific ac-
tivity 148 Ci/mmoles (Radiochemical Centre, Amersham, Unit-
ed Kingdom) to assess urinary losses. Urine samples were then
collected for 24 hr, and, at the end of the collection period, I ml
of blood was drawn from the tail artery. Urine and serum
samples (100 sl) were pipetted into scintillation vials containing
5 ml Instagel scintillation liquid (Packard Instruments, Downers
Grove, Illinois). The radioactivity was measured in a Tricarb
460 C liquid scintillation counter (Packard Instruments).
On day 105, after an overnight fast, blood was drawn from the
tail artery for the measurement of serum creatinine, calcium,
inorganic phosphate, albumin, cholesterol, triglyceride, and
250HD. A random sample of urine was obtained from the
nephrotic and control animals at that time. The radioactivity in
100 tl of urine and serum of these animals was again
determined.
Seventeen days and 3 days before the animals were due for
sacrifice (days 99 to 102 and 113 to 116, respectively), each
received a 20 mg/kg dose of demethylchlortetracycline
intraperitoneally.
Twenty-four hours before sacrifice, six nephrotic rats, five
control rats, and the five D-depleted rats received a second
intravenous injection (4.0 MCi) of 25 hydroxy-[26,27-methyl-3H1
cholecalciferol to assess the metabolism of this compound.
Urine passed during the subsequent 24 hr was collected. All
animals were killed between days 116 and 119 under light ether
anesthesia by exsanguination from the abdominal aorta. Serum
l,25(OH)2D and 24,25(OH)2D concentrations were measured in
blood collected at the time of sacrifice. In animals that had
received tritiated vitamin D3, an analysis was made of radioac-
tive metabolites. Serum and urine vitamin D-binding protein
levels were measured in the nephrotic and control animals. The
shaft of the right femur was removed for the measurement of
bone calcium concentration and the right tibia for quantitative
histomorphometry.
Methods
Serum creatinine was measured by a standard Technicon
AutoAnalyzer method, serum calcium by a fluorometric meth-
od with a "Calcette" automatic calcium analyzer (Precision
Systems Inc., Sudbury, Massachusetts), serum inorganic phos-
phate by a modification of the molybdate vanadate reaction [8],
using a kit purchased from Boehringer (Mannheim, West Ger-
many), serum albumin by the method of Doumas, Watson, and
Biggs [9], and urinary protein by the method of Henry, Sobel,
and Segalove [10]. Serum cholesterol [II] and triglyceride [12]
concentrations were measured enzymatically with an Instru-
mentation Laboratory Multistat III Micro-Centrifugal Analyzer
(Lexington, Massachusetts) using kits purchased from Boeh-
ringer (Mannheim, West Germany) and Abbott Laboratories
(South Pasadena, California), respectively. Serum calcium lev-
els were corrected for a serum albumin of 32 glliter [13]. 25-
Hydroxyvitamin D was measured by a modification [14] of the
method of Haddad and Chyu [IS].
Serum l,25(OH)2D and 24,25(OH)2D were measured by a
previously described method [16] modified as follows: Serum (2
to 3 ml) was extracted in n-hexane: isopropanol:n-butanol
(93:3:4), and the aqueous layer was frozen in liquid nitrogen.
The supernatant was decanted, shaken for 1 mm with an
approximately equal volume of 0.1 NI disodium hydrogen phos-
phate buffer, pH 10.5; the aqueous layer was again frozen. The
supernatant was decanted and evaporated to dryness under
nitrogen at 37°C. It was redissolved and applied to a Sephadex
(Pharmacia, Uppsala, Sweden) LH20 column 120 x 6 mm in a
mobile phase of n-hexane:chloroform:methanol (9.0:1.5:1.0).
The eluate was filtered (0.5 sm Teflon-Millipore, Bedford,
Massachusetts) prior to further purification by high perform-
ance liquid chromatography (HPLC) on a Zorbax-Sil (Du Pont,
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Wilmington, Delaware) silica column 4,6 x 250 mm in a mobile
phase of isopropanol: n-hexane (8:92). Fractions comigrating
with authentic 24,25(OH)2D3 and I ,25(OH)2D3 (Radiochemical
Centre, Amersham. United Kingdom) were collected and dried.
The fractions comigrating with 24,25(OH)2D3 were examined
for their ability to displace [3H]250HD from its binding site(s)
to D-binding protein. The eluate was dried, redissolved in
"lipisol" (a gift from Drs. Haussler and Dokoh, University of
Arizona, Tucson, Arizona) and incubated with human serum
diluted with diethyl barbiturate/acetate buffer, pH 8.6 (Buffer
A) and [3H]250HD tracer (TRK 558, Radiochemical Centre).
The fractions comigrating with I ,25(OH)2D3 were dissolved
in "lipisol" and incubated with cytosol prepared from normal
chick duodenum [16] and [3H]l,25(OH)2D3 (TRK 656, Radio-
chemical Centre).
After the respective incubations, 'bound" 24,25(OH)2D and
l,25(OH)2D were separated from "free" material with a 50%
slurry of hydroxylapatite in Buffer A [for 24,25(OH)2D] and
Tris-HCI, pH 7.5, [for l,25(OH)2D]. The bound fractions were
dissolved in methanol and counted in 10 ml Instagel scintillation
liquid (Packard) on a Tricarb 460 C liquid scintillation counter.
The results were read from a standard curve constructed as
previously described [16].
Vitamin D binding protein (DBP) levels were measured in the
laboratory of Dr. R. Bouillon by a method previously described
[17]. The free l,25(OH)2D index was calculated [18] as previ-
ously described.
Serum and urine samples from animals injected with
[3H]250HD3, were extracted according to the method of Shep-
ard et al [19]. The extracts were evaporated to dryness under
nitrogen, redissolved in isopropanol:n-hexane (8:92) and lii-
tered (1 m Teflon-Millipore). The filtrates were dried under
nitrogen, redissolved in 100 .d isopropanol:hexane (8:92) and
subjected to HPLC on a column 0.32 cm (internal diameter) X
25 cm (Altex, Berkeley, California) filled with "Spherisorb" (5
gm-Merck, Darmstadt, West Germany).
The HPLC system was calibrated each day with tritiated
250HD3, 24,25(OH)2D3 and 1 ,25(OH)2D3 (Radiochemical Cen-
tre). The metabolites in the serum samples from two animals
were further identified by rechromatography. Radioactive
"peaks" were collected and mixed with the appropriate nonla-
beled standard [I ,25(OH),D3, 24,25(OH)2D3 or 25,26(OH)2D3,
Roche Products Pty. Ltd., Sydney, Australia]. In each mixture,
labeled and unlabeled material was shown to comigrate on
straight and reverse phase HPLC. Radioactivity co-eluting with
individual authentic standards was expressed as a percentage of
total radioactivity recovered after HPLC.
Bone density and calcium concentrations. The femoral shaft
was scraped clean of adhering periosteal tissue, and the marrow
was removed with ajet of de-ionized water. The bone was dried
at 110°C for 16 hr, weighed in air, and then re-weighed,
suspended from a fine wire, in de-ionized water. Bone density
was calculated from the formula, density = weight in air/weight
in air — weight in water.
The femoral shaft was ashed at 600°C for 16 hr. The bone ash
was weighed, dissolved in 50 ml 2 Nnitric acid, and made up to
500 ml. Calcium was measured by atomic absorption spec-
trophotometry and expressed as a percentage of dry weight.
Bone histomorphometry. A midsagittal slice of the proximal
tibial metaphysis, approximately 1 mm in thickness was re-
moved with a Metal Research Microslice II saw (Metal Re-
Table 2. Vitamin D metabolites and vitamin D binding protein in
serum and urine of normal, nephrotic, and D-deficient rats on day
105, 8 weeks after the second injection of NTS
Normal
(N = 10)
Nephrotic
(N = 7)
D-deficient
(N = 5)
Serum 250HD,
nmolesiliter 63 18 8.9 2.Oa <8
Serum l,25(OH)2D,
pmoles/liier 90 44(N = 8)
48 30" 19 I .7°°
Serum
24,25(OH)2D,
nmoles/liter 31 10(N=8)
4.0 4.6°(N=6)
0.8 0.3°
Serum DBP, mgi
liter 537 58 349 91° NM
Free l,25(OH)2D
index (molar ratio
x 10) 0.75 0.28 0.63 0.57
Urine DBP, mg124
hr Not detectable 5.5 3.0° NM
Abbreviation: NM, Not measured.
° The value is significantly different from control (P < 0.00I).
' The value is significantly different from control (P < 0.05).
° The value is significantly different from nephrotic rats (P < 0.05).
search, Melbourn, England). It was fixed in buffered 10%
formalin-saline (pH 7.0), dehydrated in graded concentrations
of ethanol and embedded in methyl methacrylate [20]. Sections,
7-sm thick, were cut with a Jung K microtome (Heidelberg,
West Germany) and stained in 0.2% aqueous toluidine blue (pH
5.5) for 30 sec. The entire area directly beneath the growth
plates was examined. Osteoid areas and linear appositional
rates were measured with an eyepiece fitted with E 11 a and E 28
graticules (Graticules Ltd., Kent, United Kingdom), respec-
tively [211.
The linear appositional rate (sm/day) was calculated from the
mean distance between the two tetracycline markers, measured
at l00-im intervals, where double labels were found, divided
by 14, which was the number of days between the administra-
tion of the two markers.
Results
The body weights and biochemical data of normal, nephrotic
and D-deficient animals are shown in Table I. The nephrotic
syndrome with heavy proteinuria and hypoalbuminemia was
fully established 3 weeks after the second injection of NTS
while serum creatinine remained normal throughout the
experiment.
Serum vitamin D metabolites, serum DBP concentrations and
24-hr urinary DBP values are shown in Table 2. Serum 250HD,
24,25(OH)2D and 1 ,25(OH)2D concentrations were lower in the
nephrotic and D-deficient animals than in the controls. In the
nephrotic animals mean serum 2SOHD and 24,25(OH)2D con-
centrations were approximately 15% of control values whereas
the mean serum l,25(OH)2D concentration was approximately
50% that of normal rats. Serum 250HD concentrations were
significantly correlated with serum 24,25(OH),D values in the
control group (r = +0.871, P < 0.01) but not in the nephrotic
group (r = 0.591, P > 0.1).
Assuming a plasma volume of 30 mI/kg, the nephrotic animals
lost more than the total circulating DBP in 24 hr (5.47 2.99
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Table 3. Radioactivity in three groups of rat sera comigrating with
dihydroxylated vitamin D metabolites 24 hr after the intravenous
injection of 4 tCi tntiated 250HD3 (percentages of total counts in
sample)
Control(N=5) Nephrotic(N=6)
Vitamin D
deficient(N=5)
24,25(OH)2D3 6.0 0.8 11.3 2.5a 3.8 l.lb,d
25,26(OH)2D3 0.9 0.1 0.7 0.2 1.7 0.2a
l,25(OH)2D1 0.1 0.04 0.5 0.3 0.2 0.02b,
a The value is significantly different from controls (P <0.001).
b The value is significantly different from controls (P < 0.01).
The value is significantly different from controls (P < 0.02).
d Thevalue is significantly different from nephrotic rats (P < 0.001).
The value is significantly different from nephrotic rats (P < 0.05).
mg) whereas DBP was undetectable in the urine of control
animals. Serum DBP was lower in the nephrotic rats than in the
controls. The free I ,25(OH)2D index was similar in the two
groups.
During the 24-hr period after the intravenous injection of 0,5
Ci tritiated 250HD3, 34.2% of the total radioactivity was
recovered in urine samples of nephrotic animals compared with
0.4% in the controls (126,900 55,400 cpm vs. 1500 800 cpm,
P < 0.001). Serum total radioactivity 24 hr after the injection
was significantly higher in the control animals (5427 1848
cpmlml) than in the nephrotic rats (1891 887 cpm/ml, P <
0001). There was a significant correlation between serum and
urine radioactivity in the control rats (r = +0.821, P < 0.01)
whereas no such correlation could be found in the nephrotic
animals (r = +0.135, P> 0.1).
Four weeks after the injection, significant radioactivity was
still present in the serum of the control animals (852 284
cpm/ml) whereas the radioactivity in the serum of the nephrotic
rats was negligible (31 18 cpm/ml). At that stage only minimal
radioactivity was present in urine samples of controls (40 25
cpmlml) and nephrotic animals (50 16 cpm/ml).
Table 3 shows the distribution of tritiated material between
the various HPLC fractions in sera of different groups of
animals, 24 hr after the intravenous injection of 4 Ci tritiated
250HD3. In sera from nephrotic animals, a significantly greater
proportion of radioactivity comigrated with 24,25(OH)2D3 and
I ,25(OH)2D3 than in sera from control rats. In serum from the
D-deficient rats the percentage of radioactive material comi-
grating with 1,25(OH)2D3 was higher, while that comigrating
with 24,25(OH)2D3 was lower than the corresponding values in
the controls. The percentage of tritiated material comigrating
with 25,26(OH)2D3 was higher in the D-deficient animals than in
the controls and in the nephrotic animals.
Urine samples collected from nephrotic rats during the 24-hr
periods after the injection of 4 Ci [3H]250HD, showed radio-
active peaks comigrating with 250HD3 (92.7 1.5%),
24,25(OH)2D3 (5.9 1.6%), 25,26(OH)2D3 (0.5 0.3%), and
l,25(OH)2D3 (1.0 0.6%). The percentage of radioactivity
comigrating with 24,25(OH)2D3 in serum extracts from nephrot-
ic animals was significantly higher than that in urine samples (P
< 0.001). There was insufficient radioactivity in the urine
samples of non-nephrotic animals for a distribution analysis.
The bone density and calcium content of the femoral shaft as
well as bone histomorphometry of the tibial metaphysis are
shown in Table 4. There were no significant differences be-
Table 4. Density, calcium content and histomorphometry of bone
from three groups of rats
Control
(N=9) Nephrotic(N=7)
D-deficient
(N=5)
Bone density 2.34 0.06 2.33 0.05 NM
(femoral shaft, girn!)
Calcium content 37.0 1.0 37.5 1.0 NM
(femora! shaft, % ash)
Calcium content 26.0 0.8 26.6 0.8 NM
(femoral shaft, % dry
weight)
Uncalcified osteoid Absent Absent Absent
(tibia! metaphysis)
Linear appositional rate 1.72 0.38 1.84 0.20 1.71 0.06
(tibia! metaphysis rn/day)
Abbreviation: NM, Not measured.
Table 5. Mean concentrations of serum vitamin D metabolites in the
nephrotic syndrome as observed by three groups of investigators
(normal means in parentheses)
Goldstein
et al [4]a
(Human)
Lambert
et al [5]a
(Human)
This
study
(Rat)
250HD, nmo!es/!iter 10.0 (92.5) 20.3 (69.3) 8.9 (63.0)
24,25(OH)2D, nmo!es/!iter 4.3 (8.2) 1.6 (3.8) 4.0 (31.3)
l,25(OH)2D, prno!es/!iter 16.8 (88.8) 32.9 (82.1) 47.9 (89.5)
a Data converted from metric units to SI units.
tween nephrotic and normal animals in any of the parameters
measured. There was no evidence of osteomalacia in the D-
deficient animals.
Discussion
Massive urinary losses of vitamin D compounds and DBP
were observed in this study. Indeed, within 24 hr after an
intravenous injection of [3H]250HD3, 34% of the total radioac-
tivity had appeared in the urine, presumably due to heavy
urinary losses of DBP [3, 5].
As far as we are aware, there have only been two previous
studies concerning dihydroxylated vitamin D metabolites in the
nephrotic syndrome, both of them in humans (Table 5). Normal
rats have higher serum 24,25(OH)2D concentrations than nor-
mal humans [22), but in the nephrotic syndrome this difference
disappears so that similar values for all three metabolites are
observed in both species (Table 5). The serum l,25(OH)2D
values of normal rats were similar to those observed in normal
humans. The nephrotic animals, in contrast to the D-deficient
animals, retained relatively normal serum concentrations of this
metabolite (Table 2).
The difference between the serum l,25(OH)2D concentra-
tions of nephrotic animals and those of D-deficient animals may
be due to several mechanisms, Firstly, the nephrotic rats are
not totally vitamin D-depleted. Despite heavy urinary losses,
significant amounts of radioactivity remained in the circulation
24 hr after the intravenous injection of [3H]250HD3. Similar
findings were reported by Haldimann et al [23] in nephrotic
humans. This partial vitamin D depletion of nephrotic humans
and rats may lead to a preferential conversion of 250HD to
1 ,25(OH)2D [24—261.
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Secondly, while approximately 98% of 250HD3 and
24,25(OH)2D3 are attached to vitamin D binding protein (DBP),
only 62% of l.25(OH)2D3 is protein-bound [27]. Urinary losses
of DBP [1. 3] are therefore likely to affect serum levels of
250HD and 24,25(OH)2D to a greater extent than those of
1 .25(OH)2D.
Finally, circulating l,25(OH)2D has a rapid turnover with a
biological half-life of 5 to 8 hr [28, 29]. The biological half-lives
of 250HD and 24,25(OH)2D3 are much longer [29. 30] though
Kumar [31] obtained similar turnover rates for I .25(OH).D1 and
24,25(OH)2D. An increase in turnover rates due to massive
losses in urine would have a greater effect on the serum values
of metabolites with long half-lives.
It is currently not feasible to perform dynamic studies relating
to the synthetic rates of vitamin D metabolites in the rat: no
conclusions regarding such rates can be drawn from the data in
Table 3. However, the relative size of the labeled l.25(OH)2D3
peak after an intravenous bolus of [3H]250HD1 was clearly
greater in the nephrotic animals than in the other groups. The
low pool size of unlabeled 250HD in the nephrotic animals
cannot be the sole explanation of this finding. The vitamin D
deficient animals had serum 250HD concentrations comparable
to those of the nephrotic animals, but their tritiated
l,25(OH),D3 peaks were significantly lower (Table 3).
The urinary losses of [3H]250HD3 were proportionately no
greater than those of [3H]l,25(OH),D1 and cannot explain the
relatively high value of [3H]l,25(OH)2D3 in the serum of
nephrotic animals. While it is theoretically possible that extra-
renal plasma clearance rates of 1,25(OH)2D are diminished or
those of 250HD1 increased in the nephrotic syndrome, there is
no physiological reason why such changes should occur. In
addition, a recent study by Maierhofer et al [32] suggests that
plasma concentrations of l.25(OH)2D3 are determined princi-
pally by synthetic rates. Within the limitations of these consid-
erations, it seems reasonable to conclude that the synthetic rate
of l,25(OH)2D3 is unimpaired in the nephrotic syndrome.
The situation is less clear in relation to the radioactive
24,25(OH)2D3 peak which is also greater in the nephrotic
animals than in the other groups (Table 3). As expected, the
vitamin D deficient animals with their presumptive reduction in
24-hydroxylase activities showed a reduction in the labeled
24.25(OH)2D1 peak. The elevated labeled 24.25(OH)D1 peak in
nephrotic animals which was unexpected could be due to a
decreased 2SOHD pool size, to an increased synthesis of
24,25(OH)2D3 and/or a relative reduction (compared to
250HD3) in plasma clearance rates of this metabolite. While we
are unable, on the evidence available, to decide between these
hypotheses, it is likely that 24,25(OH)2D3 synthesis is not
reduced in the nephrotic syndrome.
The relative increase in the percentage of labeled material
comigrating with 25,26(OH)2D3 in D-deficiency has been ob-
served previously [33]. Its significance is unknown.
Hypocalcemia, described as a complication of the nephrotic
syndrome in humans [2—4. 34, 351 and attributed to vitamin D
deficiency, was not observed in these nephrotic rats. We
believe the absence of hypocalcemia may be due to the absence
of nitrogenous retention [36], the relatively short duration of the
nephrotic process [5], the relatively normal serum l.25(OH)2D3
values (Table 2) and the relatively high calcium intake [37]. This
last factor may have helped to prevent hypocalcemia in our
deficient animals (Table I).
The absence of skeletal changes in our nephrotic animals
contrasts with the findings of Malluche et al [38] who reported
osteomalacia and parathyroid osteopathy in six nephrotic pa-
tients with normal creatinine clearance rates. The absence of
osteomalacia may be due to the short duration of the nephrotic
syndrome in these animals. Moreover, it is known that in the
rat, vitamin D deficiency does not result in osteomalacia (Table
4) unless the animals are phosphate-deprived [39—41]. In addi-
tion, the absence of hypocalcemia and osteomalacia in these
nephrotic rats may be due to the relatively normal 'free"
concentration of I .25(OH)2D3 (Table 2). although this hypothe-
sis would not explain the absence of hypocalcemia and osteo-
malacia in the vitamin D deficient animals.
Glass et al [42] in a somewhat analogous experiment mea-
sured circulating thyroid hormones in nephrotic rats. They
suggested that the fall in binding protein in the nephrotic
animals may lead to an increased availability of the serum
substrate (T4) to cellular processes and a consequent increase in
the synthesis of the more active hormone (T). The same
speculation applies to the dihydroxylated vitamin D
metabolites.
To our knowledge, the studies reported in this paper are the
first relating to vitamin D metabolites in a nonhuman nephrotic
model.
Note added in proof
After our study was submitted for publication, Korkor et al
[43] reported normal bone histology in 6 nephrotic humans.
Korkor et al [43] also showed that while serum 2SOHD values
in the nephrotic syndromes were abnormally low, serum
l,25(OH)2D values remained relatively normal.
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